6. パーキンソン病 Parkinson disease Clinical trials / Disease details


臨床試験数 : 2,307 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

  
14 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-jRCTs051200160
24/03/202124/03/2021ZEAL studyZonisamide for the Efficacy of Sleep Abnormality in Parkinson's Disease: A Randomized Single-Blind Placebo-Controlled Trial - ZEAL Parkinson's disease
Parkinson's disease,Somnipathy;D010300
70 patients with Parkinson's disease were allocated to Zonisamide tablets (Trelief OD tablets) 1T (25mg) or placebo 1T at a time before going to bed by randomizing soft, and the efficacy of zonisamide tablet (Trelief OD tablets) for sleep is investigated comparing the parallel-group before and after administrationHiroshi KataokaNULLRecruiting>= 41age oldNot applicableBoth70Phase 2-3Japan
2JPRN-jRCTs041190126
22/02/202110/03/2020Study on efficacy and safety of zonisamide in at-risk subjects of Lewy body diseaseStudy on efficacy and safety of zonisamide in at-risk subjects of Lewy body disease - NaT-PROBEi Lewy body disease (Parkinson's disease and dementia with Lewy bodies)Arm zonisamide:
1.Two tablets of zonisamide 25mg after breakfast for 4 weeks
2.Four tablets of zonisamide 25mg after breakfast for 92 weeks
Arm placebo:
1.Two tablets of placebo after breakfast for 4 weeks
2.Four tablets of placebo after breakfast for 92 weeks
Katsuno MasahisaJapan Agency for Medical Research and DevelopmentNot Recruiting>= 50age old< 80age oldBoth30Phase 2Japan
3NCT04182399
(ClinicalTrials.gov)
April 1, 202024/11/2019Role of Zonisamide in Advanced Parkinson's Disease (PD) in Egyptian Population: Pilot StudyRole of Zonisamide in Advanced Parkinson's Disease (PD) in Egyptian Population: Pilot StudyParkinson DiseaseDrug: Zonisamide CapsulesAin Shams UniversityNULLCompleted18 YearsN/AAll69N/AEgypt
4JPRN-UMIN000024859
2016/12/1416/11/2016The effectiveness of motor and psychiatric symptoms for Parkinson's disease patients by switching from Dopamine agonist to Zonisamide or combining Dopamine agonist and Zonisamide.The effectiveness of motor and psychiatric symptoms for Parkinson's disease patients by switching from Dopamine agonist to Zonisamide or combining Dopamine agonist and Zonisamide. - The effectiveness of motor and psychiatric symptoms for Parkinson's disease patients by switching from Dopamine agonist to Zonisamide or combining Dopamine agonist and Zonisamide. Parkinson's diseaseSwitching from Dopamine agonist to Zonisamide.

Intervention period of 12 weeks.
Medical Corporation Abe Neurology ClinicNULLComplete: follow-up continuing30years-oldNot applicableMale and Female50Not applicableJapan
5JPRN-jRCTs051180098
09/06/201606/03/2019The DAT-SPECT study for the benefit of Selegilline or Zonisamide in Parkinson's DiseaseA comparative randomized study for the evaluation of the overlaying effect of Selegiline or Zonisamide over Levodopa in Parkinson's disease Parkinson's disease;034034L-Dopa/DCI only : The drug is administered per oral at 300 mg/day. The treatment is started within 14 days after registration and continued until day 365.
L-Dopa/DCI + selegiline : L-Dopa/DCI is administered per oral at 300 mg/day and selegiline is administered at 5 mg/day. The treatment is started within 14 days after registration and continued until day 365.
L-Dopa/DCI + zonisamide : L-Dopa/DCI is administered per oral at 300 mg/day and zonisamide is administered at 25 mg/day. The treatment is started within 14 days after registration and continued until day 365.
Ito HidefumiNULLNot Recruiting>= 55age old< 80age oldBoth120Phase 2Japan
6JPRN-UMIN000022533
2016/06/0101/06/2016A comparative randomized study for the evaluation of the overlaying effect of Selegiline or Zonisamide over Levodopa in Parkinson's diseaseA comparative randomized study for the evaluation of the overlaying effect of Selegiline or Zonisamide over Levodopa in Parkinson's disease - The DAT-SPECT study for the benefit of Selegilline or Zonisamide in Parkinson's Disease(DATSZ-PD study) Parkinson's diseaseL-Dopa/DCI only
The drug is administered per oral at 150 to 300 mg/day. The treatment is started within 14days after registration and continued until day 365.
L-Dopa/DCI + selegiline
L-Dopa/DCI is administered per oral at 150 to 300 mg/day and selegiline is administered at 5mg/day. The treatment is started within 14days after registration and continued until day 365.
L-Dopa/DCI + zonisamide
L-Dopa/DCI is administered per oral at 150 to 300 mg/day and zonisamide is administered at 25mg/day. The treatment is started within 14days after registration and continued until day 365.
Osaka Redcross HospitalWakayama Prefectural Medical CollegeNULLRecruiting55years-old80years-oldMale and Female180Phase 2Japan
7NCT03034538
(ClinicalTrials.gov)
April 8, 201625/1/2017An Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's DiseaseAn Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's DiseaseParkinson Disease;Parkinsonism;DyskinesiasDrug: ZonegranThe Cooper Health SystemNULLSuspended18 YearsN/AAll20Phase 4United States
8JPRN-jRCTs041180070
04/11/201507/03/2019Trerief Impact in PD PET StudyRandomized, multicenter, open-label, comparative study on neuroprotective effects of zonisamide (Trerief), anti-parkinsonian drug, in patients with early Parkinson's disease: Evaluation by functional PET (positron emission tomography) images - TIPPS Parkinson's disease
Parkinson's disease;D010300
[1] Zonisamide treatment group
Zonisamide (25 mg) once daily in addition to levodopa/DCI with fixed dosage and administration.
Note that after one-year fixed protocol period, the followings are allowed; 1) one or two tablets per day in case of developing wearing off phenomenon, 2) change of dose and/or administration of levodopa/DCI, and 3) addition of other anti-parkinsonian drugs due to exacerbation of symptoms.
[2] Zonisamide non-treatment group
Only levodopa/DCI with fixed dosage and administration.
Note that after one-year fixed protocol period, the followings are allowed; 1) change of dose and/or administration of levodopa/DCI and 2) addition of other anti-parkinsonian drugs except for zonisamide due to exacerbation of symptoms.
Ouchi YasuomiNULLNot RecruitingNot applicable< 80age oldBoth20N/AJapan
9JPRN-UMIN000019524
2015/10/0128/10/2015Randomized, multicenter, open-label, comparative study on neuroprotective effects of zonisamide (Trerief), anti-parkinsonian drug, in patients with early Parkinson's disease: Evaluation by functional PET (positron emission tomography) imagesRandomized, multicenter, open-label, comparative study on neuroprotective effects of zonisamide (Trerief), anti-parkinsonian drug, in patients with early Parkinson's disease: Evaluation by functional PET (positron emission tomography) images - Trerief Impact in PD PET Study (TIPPS) Parkinson's DiseaseZonisamide treatment group:

Zonisamide (25 mg) once daily in addition to levodopa/DCI with fixed dosage and administration.
Note that after one-year fixed protocol period, the followings are allowed; 1) one or two tablets per day in case of developing wearing off phenomenon, 2) change of dose and/or administration of levodopa/DCI, and 3) addition of other anti-parkinsonian drugs due to exacerbation of symptoms.
Zonisamide non-treatment group:

Only Levodopa/DCI with fixed dosage and administration.
Note that after one-year fixed protocol period, the followings are allowed; 1) change of dose and/or administration of levodopa/DCI and 2) addition of other anti-parkinsonian drugs except for zonisamide due to exacerbation of symptoms.
Hamamatsu University School of MedicineNULLComplete: follow-up completeNot applicable80years-oldMale and Female20Not applicableJapan
10JPRN-UMIN000010371
2013/04/0801/04/2013Study of zonisamide ( TRERIEF&reg; tablet 25mg ) to tremor in patients with early Parkinson's disease.Study of zonisamide ( TRERIEF&reg; tablet 25mg ) to tremor in patients with early Parkinson's disease. - Study of zonisamide to tremor in patients with early Parkinson's disease. Parkinson's diseaseStart 25mg of Zonisamide and carry out observation 24weeks.
Evaluate start point, after 4weeks, after 8weeks, after 16weeks, and after 24weeks.
Department of Neurology, University of YamanashiNULLPendingNot applicableNot applicableMale and Female10Not selectedJapan
11NCT01766128
(ClinicalTrials.gov)
February 20138/1/2013Study of Zonisamide in Early Parkinson DiseaseRandomized Double Blind Placebo-controlled Study of Zonisamide Effectiveness in Early Parkinson DiseaseParkinson DiseaseDrug: Zonisamide;Drug: PlaceboMazandaran University of Medical SciencesNULLWithdrawn45 Years85 YearsAll0Phase 2/Phase 3NULL
12JPRN-JapicCTI-101198
01/4/2010A double-blind confirmatory study for AD-810N (zonisamide) in patients with Parkinson's disease (Phase III)A double-blind confirmatory study for AD-810N (zonisamide) in patients with Parkinson's disease (Phase III) Parkinson's diseaseIntervention name : Zonisamide
Dosage And administration of the intervention : Oral
Control intervention name : null
Dainippon Sumitomo Pharma Co., Ltd.NULL2074BOTH360Phase 3NULL
13JPRN-JapicCTI-050099
12/09/2005Double blind, parallel-group clinical study of AD-810N (zonisamide) for Parkinson's diseaseDouble blind, parallel-group clinical study of AD-810N (zonisamide) for Parkinson's disease Parkinson's diseaseIntervention name : AD-810N (zonisamide)
Dosage And administration of the intervention : oral
Dainippon Sumitomo Pharma Co., Ltd.NULL2079BOTHNANULL
14JPRN-JapicCTI-070377
28/03/2007Double-blind, parallel-group confirmatory study of AD-810N (zonisamide) in patients with Parkinson's diseaseDouble-blind, parallel-group confirmatory study of AD-810N (zonisamide) in patients with Parkinson's disease Parkinson's diseaseIntervention name : AD-810N (zonisamide)
Dosage And administration of the intervention : oral
Dainippon Sumitomo Pharma Co., Ltd.NULL2074BOTHPhase 3NULL